Tecentriq-Cotellic Combo Fails to Lengthen Survival in Advanced Colorectal Cancer
News
A combination treatment of Tecentriq (atezolizumab) and Cotellic (cobimetinib) did not extend survival of patients with advanced or difficult-to-treat colorectal cancer (CRC) compared to standard therapy, Roche’s Phase 3 clinical ... Read more